United Therapeutics
$541.70Change from previous close: −5.19%Absolute change: −$29.68
At a glance
- Revenue growth
- +10.61%
- 2025 vs 2024
- Net income growth
- +11.68%
- 2025 vs 2024
- Net margin
- 41.9%
- 2024: 41.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 1,561 | 1,327 | 978 | 803 | — |
| Depreciation and amortization | 85.6 | 72.5 | 53.2 | 51.3 | — |
| Capital expenditure | -526 | -247 | -230 | -139 | — |
| Investing cash flow | -551 | 417 | -720 | -812 | — |
| Financing cash flow | -1,150 | -1,255 | -11.9 | 75.4 | — |
| Share repurchases | -1,017 | -1,012 | -13.8 | -11.4 | — |
| Debt issued | 200 | 0.0 | 0.0 | 800 | — |
| Debt repaid | -500 | -400 | -100 | -800 | — |
| Net change in cash | -140 | 490 | 247 | 66.4 | — |
| Free cash flow | 1,035 | 1,081 | 748 | 664 | — |